PDE4B-IN-6
PDE4B-IN-6 (compound 4i) is a potent and selective PDE4B inhibitor with an IC50 of 7.42 nM. PDE4B-IN-6 shows ~195- and ~169-fold selectivity for PDE4B over PDE4A (IC50 = 1540 nM) and PDE4C (IC50 = 1260 nM), respectively. PDE4B-IN-6 increases cAMP level and suppresses TNF-α expression. PDE4B-IN-6 shows favorable antioxidant profiles and low cytotoxicity. PDE4B-IN-6 can be used for chronic obstructive pulmonary disease (COPD) research[1].
Product Specifications
UNSPSC
12352005
Target
Phosphodiesterase (PDE) ; TNF Receptor
Related Pathways
Apoptosis; Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
O=C(NNC(C1=CC=C(OC(F)F)C(OCC2CC2)=C1)=O)C3=CC(OC)=C(OC)C(OC)=C3
Molecular Formula
C22H24F2N2O7
Molecular Weight
466.43
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PDE4
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
FXN, CT (Frataxin, Mitochondrial, Friedreich Ataxia Protein, Frataxin Intermediate Form, Frataxin (56-210), Frataxin (81-210), FRDA, X25) (FITC) discontinued